The PV automation misnomer.
Are life sciences companies still missing opportunities to lighten safety reporting workloads?
Across all facets of the industry, on both sides of the Atlantic, and between Pharmacovigilance, Drug Safety and Product Safety teams, there is evidence that teams are still not benefiting fully from today’s process automation potential, to enhance delivery of the important work they do.
Typically, companies have implemented automation in fairly limited and focused ways that make only a small impact on overall PV operations (an example being auto-listedness)…
